AI Article Synopsis
- CDC25 is a dual phosphatase that has been identified as a key target for various triple-negative breast cancers, especially those lacking certain genetic features.
- Inhibitors that block CDC25 show promising results when combined with PI3K inhibitors, leading to better suppression of tumor growth.
- The text highlights the potential of CDC25 inhibitors in cancer treatment while also addressing the challenges of making these treatments available in clinical settings.
Article Abstract
The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including -deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149702 | PMC |
| http://dx.doi.org/10.1080/23723556.2018.1481814 | DOI Listing |
Publication Analysis
Top Keywords
triple-negative breast
8
cdc25 inhibitors
8
cdc25
4
cdc25 common
4
common therapeutic
4
therapeutic target
4
target triple-negative
4
breast cancer
4
cancer challenges
4
challenges ahead
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!